-
Something wrong with this record ?
Osteopontinspiegel im Plasma bei dilatativer und hypertrophischer Kardiomyopathie [Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy]
J. Podzimkova, T. Palecek, P. Kuchynka, J. Marek, BA. Danek, M. Jachymova, M. Kalousova, T. Zima, A. Linhart,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2005-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Cardiomyopathy, Dilated * blood MeSH
- Cardiomyopathy, Hypertrophic * blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Myocardium MeSH
- Natriuretic Peptide, Brain MeSH
- Osteopontin * blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. PATIENTS AND METHODS: We examined plasma OPN as well as creatinine, C‐reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. RESULTS: Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 ± 43 vs. 57 ± 21 ng/ml; p < 0.001) and control subjects (54 ± 19 ng/ml; p < 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively). CONCLUSION: Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.
Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045585
- 003
- CZ-PrNML
- 005
- 20240125143448.0
- 007
- ta
- 008
- 200109s2019 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00059-017-4645-3 $2 doi
- 035 __
- $a (PubMed)29147972
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Podzimkova, J $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 245 10
- $a Osteopontinspiegel im Plasma bei dilatativer und hypertrophischer Kardiomyopathie / $c J. Podzimkova, T. Palecek, P. Kuchynka, J. Marek, BA. Danek, M. Jachymova, M. Kalousova, T. Zima, A. Linhart,
- 246 31
- $a Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy.
- 520 9_
- $a BACKGROUND: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. PATIENTS AND METHODS: We examined plasma OPN as well as creatinine, C‐reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. RESULTS: Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 ± 43 vs. 57 ± 21 ng/ml; p < 0.001) and control subjects (54 ± 19 ng/ml; p < 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively). CONCLUSION: Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.
- 650 12
- $a dilatační kardiomyopatie $x krev $7 D002311
- 650 12
- $a hypertrofická kardiomyopatie $x krev $7 D002312
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myokard $7 D009206
- 650 _2
- $a natriuretický peptid typu B $7 D020097
- 650 12
- $a osteopontin $x krev $7 D053495
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Palecek, T $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic. tpalec@lf1.cuni.cz.
- 700 1_
- $a Kuchynka, P $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Marek, J $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Danek, Barbara Anna $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic. $7 xx0313114
- 700 1_
- $a Jachymova, M $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Kalousova, M $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Zima, T $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Linhart, A $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic.
- 773 0_
- $w MED00002031 $t Herz $x 1615-6692 $g Roč. 44, č. 4 (2019), s. 347-353
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29147972 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20240125143442 $b ABA008
- 999 __
- $a ok $b bmc $g 1483853 $s 1084258
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 44 $c 4 $d 347-353 $e 20171116 $i 1615-6692 $m Herz $n Herz $x MED00002031
- LZP __
- $a Pubmed-20200109
